A new Covid clinical trial will assess the efficacy of the third vaccine.
TODAY, the Department of Health and Social Care announced that a new clinical trial to investigate the efficacy of a third Covid vaccine has been approved.
People with weaker immune systems will be given the Pfizer, Moderna, and Novavax Covid vaccinations. Scientists want to know if a third jab is truly necessary. The project, which is funded by the British government, builds on the findings of the OCTAVE trial. Researchers discovered that 89 percent of persons who are immunocompromised or immunosuppressed produce antibodies in the OCTAVE trial.
Furthermore, only 60% of patients had a robust antibody response after two doses, according to the findings.
A study has now been allowed to see if a third Covid vaccine will help people with compromised immune systems enhance their immunological response.
The £2.2 million study, dubbed “OCTAVE DUO,” will build on the findings of the first clinical trial, which was headed by the University of Glasgow.
According to the findings of the first research, after two Covid vaccines, 40% of persons with weakened immune systems had “undetectable” immunological responses.
The amount of antibodies needed to protect against COVID-19 is currently unknown.
T cells, on the other hand, are thought to play a key role in defending humans from the virus.
As a result, the findings of the first experiment cannot be used to provide a definitive assessment of the level of protection provided by vaccines.
Those who volunteered for the original trial will be contacted again for the follow-up trial.
The findings are scheduled to be released later this year.
This information will be used to inform the UK’s Covid vaccination deployment program in these high-risk categories.
Patients’ immunological responses will be regularly evaluated until mid-2022.
“Vaccines have constructed a strong wall of defense in the UK, and this is helping most of us to learn to live safely with COVID-19,” said Health and Social Care Secretary Sajid Javid.
“We know that some people may be less protected by the vaccine than others, so we’re preparing a booster campaign in the fall, focusing on those who are most vulnerable.
“This new study will be critical in helping to define the deployment of future vaccination doses for these at-risk populations.”
Patients with the following conditions are included in the OCTAVE DUO study:
“Brinkwire Summary News,” says Dr. Rob Buckle, Chief Scientist of the Medical Research Council, which is part of UKRI.